Get your free personalized podcast brief
We scan new podcasts and send you the top 5 insights daily.
The traditional model of cheaply in-licensing early-stage molecules from China for development in the West is disappearing as valuation gaps close. Investors and biopharma companies must pivot toward collaborative joint ventures that grant local Chinese innovators pipeline equity.
Related Insights
Western pharma firms strategically license assets from Chinese biotechs while leaving China rights with the local partner. This leverages China's faster, cheaper clinical development, as the partner tests the molecule in new indications, generating valuable data that de-risks the asset for the global firm at no extra cost.
Western pharmaceutical companies are no longer seeking cheap 'me-too' assets in China. Instead, they are paying premium prices for genuinely innovative drugs, as evidenced by a 10x increase in deal size over five years and a surge in patent filings from the region.
Forbion identified an arbitrage: promising biotech assets in China whose originators lacked global development expertise. Their strategy is to create new Western companies, in-license these assets, and install an experienced team to unlock their "rest of world" value, a model proven by a billion-dollar exit.
China has developed a first-rate biotech effort, enabling U.S. firms to buy or license preclinical assets more efficiently than building them domestically. This creates an arbitrage opportunity, leveraging China's R&D capabilities while relying on U.S. expertise and capital for global commercialization.
Candid's rapid acquisition by UCB for $2B showcases a profitable strategy: in-licensing promising but undervalued drug assets from China's innovation hub and quickly developing them for a Western market exit. This model leverages a significant valuation arbitrage between the two ecosystems.
A trio of significant deals in one week—Novo Nordisk, Merck, and Novartis all partnering with Chinese biotechs—underscores a major trend. Western pharmaceutical giants are now aggressively sourcing early-stage, preclinical assets from China to fuel their global R&D pipelines.
Western pharmaceutical giants face losing $400 billion in annual revenue as major drug patents expire. This forces them to urgently acquire new drug assets to fill the gap, making China's increasingly innovative, fast, and cost-effective biotech ecosystem a primary and necessary source for their future pipelines.
The appeal of Chinese biotech is evolving beyond just drug assets. Western firms are now attracted to the "China way" of rapid, low-cost innovation. Deals are increasingly structured to gain access to Chinese talent and their efficient development methodologies, recognizing the process itself as a valuable asset.
Big Pharma is increasingly licensing assets from Chinese biotechs, putting the region on par with Europe as a source of innovation. However, outright M&A of Chinese firms is a complete non-starter. This reflects a bifurcated strategy: pharma will partner for assets but avoids the geopolitical and logistical headaches of acquisitions, creating a 'license-only' pipeline from China.
In a major strategic shift, large pharmaceutical companies are increasingly sourcing their M&A pipeline from China. Chinese assets now account for 30-40% of Big Pharma's early-stage acquisitions, up from single digits just a few years ago, primarily because they are significantly cheaper than US or European equivalents.
